DUBLIN, Feb. 29,
2024 /PRNewswire/ -- Medtronic (NYSE:MDT), the
global leader in healthcare technology, today announced it filed a
complaint with the U.S. International Trade Commission (ITC), along
with a parallel action in U.S. District Court for the District of
Delaware, to block Axonics from
improperly importing and selling products that infringe two
Medtronic patents related to the MRI compatibility of implantable
medical devices.
"Medtronic is continuing our efforts to stop Axonics from
profiting off of their unauthorized use of our innovations and
intellectual property," said Mira
Sahney, president of the pelvic health business in the
neuroscience portfolio at Medtronic. "The pattern is clear: Axonics
uses Medtronic technologies to improperly compete in the market. It
is time for Axonics to be held accountable for these unlawful
acts."
Medtronic is asking the ITC to investigate and exclude the
importation of the infringing Axonics products into the United States.
Medtronic currently has a separate infringement suit pending in
the U.S. District Court for the Central District of California in which it asserts that Axonics
has infringed additional technologies developed by and belonging to
Medtronic.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 95,000+ passionate people
across more than 150 countries. Our technologies and therapies
treat 70 health conditions and include cardiac devices, surgical
robotics, insulin pumps, surgical tools, patient monitoring
systems, and more. Powered by our diverse knowledge, insatiable
curiosity, and desire to help all those who need it, we deliver
innovative technologies that transform the lives of two people
every second, every hour, every day. Expect more from us as we
empower insight-driven care, experiences that put people first, and
better outcomes for our world. In everything we do, we are
engineering the extraordinary. For more information on Medtronic
(NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on
Twitter and LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
Laurel Hood
|
Ryan
Weispfenning
|
Public Relations
|
Investor
Relations
|
+1-763-514-0249
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-files-itc-action-against-axonics-to-stop-unauthorized-use-of-medtronic-innovations-302075739.html
SOURCE Medtronic plc